Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early PEG-rhGH Therapy for Cognitive Development in SGA Infants
NCT05144035Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2022
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of peg-somatropin in Small for gestational age (SGA) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Total Development Quotient at 104 weeks and Head Circumference Standard Deviation Score at 104 weeks. Started Apr 2022; status: recruiting.
02
Drugs
peg-somatropin
03
Conditions
Small for gestational age (SGA)
Beyond the preview
Go deeper on NCT05144035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144035.